Payers won’t let these products break the bank.
Ira Studin, PhD
Advertisement
Articles by Ira Studin, PhD
Conditions require a disciplined approach to drug pricing.
Shift focus in orphan and ultra-orphan messaging to clinical benefit.
Supporting health plan clinical preparation and financial modeling.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
US News & World Report Reveals 2026 Best Medicare Advantage and Part D Companies
2
Cold Chain Technologies, Teva, and Kuehne+Nagel Proves Sea Freight Viable for High-Value Pharma Shipments
3
HDA 2025 Traceability Seminar: Pharma Supply Chain Nears Full DSCSA Compliance
4
AstraZeneca Expands Texas Manufacturing Facility to Double Production of Hyperkalemia Drug
5
